News

Number of Clinical Trials in Oncology has increased strongly during the last 10 years

Cancer cases and cancer related deaths continue to increase globally. While new cancer therapies are being identified offering new options for patients, many patients continue to live with cancer as a chronic disease. Nevertheless, many still succumb to their disease. In 2015, there were nearly...

New TNM- and RADS-Classification in mint Lesion

With the aid of various clinical reading templates, mint Lesion provides context-specific support in the application of established radiological criteria and guidelines for a more efficient investigation and documentation of radiological findings. Mint Lesion employs a structured approach to interpreting relevant findings in medical images so...

New mint Lesion 3.4 Software presented at RSNA 2017

With mint Lesion 3.4, reproducible assessment and structured reporting of significant image observations are easier than ever.   Numerous improvements and new functionalities related to the image data handling and display streamline the image assessment. As such, for instance, a refined image series browser provides...

ESOI/EORTC Workshop in Barcelona: Participants practice tumour response assessment using mint Lesion™

The autumn workshop of the European Society of Oncological Imaging (ESOI) and the European Organisation for Research and Treatment of Cancer (EORTC) is a 2.5 day interactive hands-on course that aims at training radiologists and radiology residents in the area of criteria-based tumour response assessment....

Mint Medical showcases MSK-Prototype at IMR 2017 in Hamburg

Mint Medical was one of the sponsors of the first Intensive course Musculoskeletal Radiology (IMR) which took place on September 8th and 9th 2017 in Hamburg. It was organized by the board of the AG Bildgebende Verfahren des Bewegungsapparats. PD Dr. Marc Regier, its chairman,...

A look ahead with mint Lesion 3.3

Mint Medical is pleased to announce the recent release of their software product version 3.3 of mint LesionTM which was completed during recent weeks. Mint Medical CEO, Dr. Matthias Baumhauer provides his  insight as to what can be expected in this highly anticipated version of...

New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany

Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen, Germany had already begun to implement this new response criteria into their  clinical routine using mint LesionTM. The iRECIST guidelines are intended to provide...

Mrs. Kelie Luby joins Mint Medical’s team

Mrs. Kelie Luby will join Mint Medical’s team from January 2017 as new Vice President Clinical Trials Software and will be introduced at the upcoming RSNA congress in Chicago.   Kelie is an experienced medical scientist and communicator with more than 18 years of clinical...

Novel oncologic therapy response criteria (iRECIST and more)

Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and prediction of treatment response.   At RSNA 2016, Mint Medical showcases a comprehensive set of new criteria including mRECIST mesothelioma, the Lugano (Cheson 2014 lymphoma)…

Customized templates in mint Lesion 3.3

mint Lesion™ 3.3 features a novel data and knowledge modelling core that enables you to customize read procedures and reporting templates – or design them easily yourself.   Among the new oncologic screening and staging guidelines, we introduce comprehensive support for ACR BI-RADS®, a refined…